Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis
- Conditions
- Colon Cancer Liver Metastasis
- First Posted Date
- 2015-12-16
- Last Posted Date
- 2015-12-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT02631564
- Locations
- 🇨🇳
Fudan University Zhongshan Hospital, Shanghai, Shanghai, China
Neoadjuvant Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin in Breast Cancer With TEKT4 Variations
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 91
- Registration Number
- NCT02628613
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2017-10-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 82
- Registration Number
- NCT02618356
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Radiation: hypofractionated whole breast irradiation with simultaneously integrated boost
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT02617043
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery
- Conditions
- Breast Cancer
- Interventions
- Radiation: partial breast irradiation
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2015-11-30
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 828
- Registration Number
- NCT02617082
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes
- Conditions
- Breast Cancer
- Interventions
- Radiation: axillary radiotherapy
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2015-11-23
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 475
- Registration Number
- NCT02612012
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
Platinum Rechallenge in Patients With Platinum-sensitive mTNBC
- First Posted Date
- 2015-11-17
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 84
- Registration Number
- NCT02607215
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1
Phase 3
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 360
- Registration Number
- NCT02605265
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Analgesia Effects of Nalbuphine vs Sulfentanil
Not Applicable
- Conditions
- C.Delivery; Surgery (Previous), Gynecological
- Interventions
- First Posted Date
- 2015-11-13
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT02604797
Incision Pain and Uterine Contraction Pain After Cesarean Section
Not Applicable
- Conditions
- C.Delivery; Surgery (Previous), Gynecological
- Interventions
- Drug: Group SF1Drug: Group S1Drug: Group SF2Drug: Group S2
- First Posted Date
- 2015-11-03
- Last Posted Date
- 2015-11-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT02595333
© Copyright 2025. All Rights Reserved by MedPath